Postoperative Radiotherapy in Head and Neck Mucosal Melanoma

Authors:
  • JTJuliette Thariat
    Juliette Thariat
  • STStephane Temam
    Stephane Temam
  • OMOlivier Malard
    Olivier Malard
  • CFCarmen Florescu
    Carmen Florescu
  • OCOlivier Choussy
    Olivier Choussy
  • MMMarc Makeieff
    Marc Makeieff
  • GPGilles Poissonnet
    Gilles Poissonnet
  • CRChristian Righini
    Christian Righini
  • BTBruno Toussaint
    Bruno Toussaint
  • JGJean Lacau St Guily
    Jean Lacau St Guily

Abstract
Head and neck mucosal melanoma (HNMM) is a rare tumor, representing 3% of all melanoma cases and 0.4% to 10% of head and neck melanomas.1 The therapeutic strategy includes surgery alone or followed by postoperative radiotherapy. When the surgical approach is not feasible, radiotherapy is often used, sometimes in combination with chemoimmunotherapy in a palliative setting. Because most studies in the literature have focused on the results of the surgical approach, the potential role of radiotherapy has not been defined. Since the first description of HNMM, the largest retrospective studies of the Rare Cancer Network2 and the Gustave Roussy Institute3 have included 59 and 69 cases, respectively. While these 2 studies have shown a benefit in the local control of tumors by postoperative radiotherapy, there remains great skepticism, mostly among head and neck surgeons. No prospective trials have been or will likely be performed, owing to the rarity of the disease.

This publication has 14 references indexed in Scilit: